NeuroSense Therapeutics Ltd. financial data

Symbol
NRSN, NRSNW on Nasdaq
Location
Herzliya, Israel
Fiscal year end
31 December
Latest financial report
20-F - Q4 2024 - 07 Apr 2025

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23,228,941 shares 51%
Common Stock, Shares, Outstanding 24,602,405 shares 36%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $666,000 USD -45%
Assets, Current $1,556,000 USD -3.9%
Property, Plant and Equipment, Net $63,000 USD -18%
Operating Lease, Right-of-Use Asset $42,000 USD -66%
Assets $1,684,000 USD -8.5%
Employee-related Liabilities, Current $498,000 USD -66%
Liabilities, Current $2,203,000 USD -37%
Operating Lease, Liability, Noncurrent $36,000 USD
Liabilities $2,203,000 USD -38%
Retained Earnings (Accumulated Deficit) $41,369,000 USD -28%
Stockholders' Equity Attributable to Parent $519,000 USD 70%
Liabilities and Equity $1,684,000 USD -8.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 90,000,000 shares 50%
Common Stock, Shares, Issued 24,602,405 shares 36%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $666,000 USD -45%
Deferred Tax Assets, Valuation Allowance $7,130,000 USD 48%
Deferred Tax Assets, Gross $7,149,000 USD 47%
Operating Lease, Liability $73,000 USD 5.8%
Lessee, Operating Lease, Liability, to be Paid $75,000 USD -51%
Property, Plant and Equipment, Gross $126,000 USD 2.4%
Operating Lease, Liability, Current $73,000 USD 5.8%
Lessee, Operating Lease, Liability, to be Paid, Year One $75,000 USD 1.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,000 USD -80%
Deferred Tax Assets, Operating Loss Carryforwards $5,688,000 USD 72%
Deferred Tax Assets, Net of Valuation Allowance $7,130,000 USD 48%